Insider Transaction Report for Arcellx, Inc.

David Charles Lubner, a director at Arcellx, Inc., reported a series of transactions on April 28, 2026, related to the company's acquisition by Gilead Sciences, Inc. through a merger agreement. All outstanding stock options with an exercise price below the merger's closing amount of $115.00 per share were canceled and converted into the right to receive a cash payment. This payment equals the difference between the closing amount and the exercise price, multiplied by the number of shares subject to the option. Additionally, each option holder received one contingent value right (CVR) per share, representing a right to a future payment of $5.00, as per the merger agreement terms. Lubner also disposed of 21,659 shares of Common Stock. Following these transactions, his post-disposition share balance is reported as zero. The report indicates that these transactions are not subject to Section 16 of the Securities Exchange Act.